Kidney Diseases Clinical Trial
Official title:
Comparison of the 100 W Holmium Laser Lithotripsy Rate Versus LithoClast Trilogy EMS in Percutaneous Mini-nephrolithotomy for Patients With Kidney Stones GUY's 1 and 2: Randomized Clinical Trial
The desire to reduce complications related to percutaneous access and morbidity related to
tract size has led researchers to evaluate PCNL using smaller-caliber instruments. In this
context, mini-PCNL has emerged. Its efficacy and safety have been demonstrated at the cost of
a lower stone-free rate.
The effectiveness of existing Ho: YAG lasers is limited by the need for manual removal of
stone fragments and mobilization of them due to the lack of a simultaneous aspiration system.
Consequently, this has been associated with long surgical times to achieve stone-free status.
This requires multiple insertions and extractions of the nephroscope to facilitate the
recovery of all fragments. This repeated step can cause the safety rails to be inadvertently
removed or the sheaths to be disinserted. Sometimes compromising surgical results.
Faced with this situation, the search for better and more efficient energy sources still
continues. With this, modern lithotripters have emerged that combine energy sources and work
more efficiently than any of them independently and, consequently, improve stone removal.
Cyberwand ™ (Olympus, Tokyo, Japan), Swiss Lithoclast® Master / Select (EMS SA, Switzerland /
Boston Scientific, Marlborough, MA, USA) and Shockpulse-SE ™ (Olympus, Tokyo, Japan) are some
examples; although they have their own set of advantages, none have proven to be superior to
any other.
As previously discussed, ballistic-ultrasonic lithotripsy combines ultrasonic and ballistic
energy together with a suction system with encouraging results in terms of a shorter
lithotripsy time and the respective economic impact of fewer surgical events and less
operating time required for the stone removal.
Therefore, it is convenient to make a comparison between the results of lithotripsy with Ho:
YAG laser energy and lithotripsy with LithoClast Trilogy EMS; and thereby determine which is
the most effective method in the resolution of kidney stones through a miniaturized
percutaneous tract.
Background The tools used for fragmentation and stone extraction have been improving over
time. Commonly available lithotripsy power sources are classified as ultrasonic, kinetic,
electrohydraulic, or combination, however, laser is the most widely used lithotripsy device
in mini-PCNL as it is a small diameter power source.
Laser lithotripsy The holmium laser has been very effective in the fragmentation of stones of
variable hardness and very safe due to its low depth of penetration (0.5 mm).
One of the advantages of the Ho: YAG laser is that it offers relatively quick lithotripsy
while minimizing tissue trauma. Furthermore, it is effective against all stone compositions,
including cystine and calcium oxalate monohydrate, where ultrasonic lithotripsy may have
difficulties.
The removal of smaller fragments is possible using a vacuum effect where the fragments are
moved from a high pressure zone in the pyelocaliceal system to a lower pressure zone in the
sheath. If there are too many fragments, this requires multiple insertions and extractions of
the nephroscope to facilitate the recovery of all of them. This repeated step can cause
inadvertent movements that affect the results.
Combined ballistic-ultrasonic lithotripsy LithoClast Trilogy EMS is the newest model of
percutaneous lithotripsy technology that provides electromagnetic and ultrasonic ballistic
energy, as well as suction capacity under the control of the surgeon through a single pedal.
Laboratory studies have suggested that combined ballistic-ultrasonic lithotripsy offers
faster stone clearance than other combined and ultrasonic devices. In an in vitro comparison,
LithoClast Trilogy EMS had the fastest average removal time of 23.79 seconds. This was
followed by ShockPulse (46.04 seconds), Select-US (54.86 seconds), and Select-USP (102.48
seconds).
In a multi-institutional study, LithoClast Trilogy EMS was evaluated, the experience of
surgeons with this device was perceived as highly satisfactory, with an excellent safety and
durability profile. The average stone removal rate was 68.9 mm2 / minute. High tissue safety
and an optimized aspiration configuration were reported in a prospective clinical trial. In
this study, the mean stone volume clearance ratios were 370.5 ± 171 mm3 / min and 590.7 ± 250
mm3 / min for mini-PCNL and PCNL, respectively.
LithoClast Trilogy EMS has a single probe design and connects to the handpiece and oscillates
with a piezoelectric ultrasonic generator at a rate of 24 kHz. At the same time, an
electromagnetic generator produces ballistic motion of the entire probe at an adjustable
speed of up to 12 Hz. As with other ultrasound-based devices, suction is available through
the hollow probe, with the foot pedal controlling the aspiration and activation of
lithotripsy. The strength of the ultrasonic vibration, the aspiration and the ballistic
energy discharge frequency are adjustable through a touch screen on the generator. Various
probe sizes are available (3.3 F, 4.5 F, 5.7 F, 10.2 F, and 11.7 F catheter).
JUSTIFICATION The desire to reduce complications related to percutaneous access and morbidity
related to tract size has led researchers to evaluate PCNL using smaller-caliber instruments.
In this context, mini-PCNL has emerged. Its efficacy and safety have been demonstrated at the
cost of a lower stone-free rate.
The effectiveness of existing Ho: YAG lasers is limited by the need for manual removal of
stone fragments and mobilization of them due to the lack of a simultaneous aspiration system.
Consequently, this has been associated with long surgical times to achieve stone-free status.
This requires multiple insertions and extractions of the nephroscope to facilitate the
recovery of all fragments. This repeated step can cause the safety rails to be inadvertently
removed or the sheaths to be disinserted. Sometimes compromising surgical results.
Faced with this situation, the search for better and more efficient energy sources still
continues. With this, modern lithotripters have emerged that combine energy sources and work
more efficiently than any of them independently and, consequently, improve stone removal.
Cyberwand ™ (Olympus, Tokyo, Japan), Swiss Lithoclast® Master / Select (EMS SA, Switzerland /
Boston Scientific, Marlborough, MA, USA) and Shockpulse-SE ™ (Olympus, Tokyo, Japan) are some
examples; although they have their own set of advantages, none have proven to be superior to
any other.
As previously discussed, ballistic-ultrasonic lithotripsy combines ultrasonic and ballistic
energy together with a suction system with encouraging results in terms of a shorter
lithotripsy time and the respective economic impact of fewer surgical events and less
operating time required for the stone removal.
Therefore, it is convenient to make a comparison between the results of lithotripsy with Ho:
YAG laser energy and lithotripsy with LithoClast Trilogy EMS; and thereby determine which is
the most effective method in the resolution of kidney stones through a miniaturized
percutaneous tract.
PROBLEM STATEMENT What is the difference of the lithotripsy rate with LithoClast Trilogy EMS
compared to 100 W Holmium laser for patients with kidney stones GUY's 1 and 2 in percutaneous
mini nephrolithotomy?
HYPOTHESIS H0: Lithotripsy performed with LithoClast Trilogy EMS in patients with GUY's 1 and
2 kidney stones undergoing percutaneous mini nephrolithotomy has a higher lithotripsy rate
than that performed with a 100W Holmium laser.
Hi: Lithotripsy performed with LithoClast Trilogy EMS in patients with GUY's 1 and 2 kidney
stones undergoing percutaneous mini nephrolithotomy has a lower lithotripsy rate than that
performed with a 100W Holmium laser.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03545113 -
Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
|
N/A | |
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT05036850 -
China Kidney Patient Trials Network
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01679587 -
Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)
|
Phase 1 | |
Completed |
NCT01155141 -
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
|
Phase 4 | |
Completed |
NCT00755690 -
Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Completed |
NCT03213158 -
Ixazomib for Desensitization
|
Phase 2 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Recruiting |
NCT06067867 -
Kidney and Pregnancy Registry
|
||
Recruiting |
NCT04110080 -
Enhanced Recovery After Surgery in Kidney Transplant Donors
|
N/A | |
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Active, not recruiting |
NCT04631965 -
Healthcare Transition of Adolescents With Chronic Health Conditions
|
||
Completed |
NCT03394859 -
Electronic Medical Records and Genomics (eMERGE) Phase III
|
||
Completed |
NCT03358966 -
Energy Expenditure in Chronic Kidney Disease
|
N/A |